Login to Your Account

Financings NEWS
Belgium's Celyad SA (formerly Cardio3 Biosciences SA) followed the footsteps of its European biotech brethren by filing with the SEC for a U.S. IPO.
LONDON – Psioxus Ltd. has raised £25 million (US$38.5 million) in a series C round that will enable the company to fund a phase I trial of its oncolytic virus enadenotucirev (Enad) in combination with an immune checkpoint inhibitor.
HONG KONG – With a focus on developing treatments for ocular fibrosis and inflammation, a new Australian biopharmaceutical company Occurx Pty Ltd. launched yesterday with A$6.5 million (US$5.2 million) in funds from a consortium that includes the Medical Research Commercialization Fund (MRCF), Brandon Capital Partners and Uniseed.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: